“PFS”- What is a Plaintiff Fact Sheet?
A Plaintiff Fact Sheet (“PFS”) is a court mandated questionnaire plaintiffs must fill out in the discovery phase of litigation. During discovery, the parties exchange information. Normally, this is done through interrogatories and requests for production, but in Multidistrict Litigations (“MDL”) and other consolidated proceedings, plaintiffs submit information to defendants by completing Plaintiff Fact Sheets. […]
Bard Hernia Mesh Case Update
The second trial in the Bard hernia mesh MDL (MDL 2846; In Re: Davol, Inc./C.R. Bard, Inc., Polypropylene Hernia Mesh Products Liability Litigation) just concluded. Thankfully, it resulted in a verdict for the plaintiffs. What are the trials about? Plaintiffs filed suit for injuries sustained after having mesh manufactured by C.R. Bard., Inc. (“Bard”) implanted […]
What is an MDL or Multidistrict Litigation?
Multidistrict Litigation, or MDL, is the consolidation of cases that involve common questions of fact. The cases are centralized in one court, and one judge oversees all pretrial discovery (taking of depositions and exchange of documents and information). How is an MDL created? Seven federal judges serve on the Judicial Panel on Multidistrict Litigation, known […]
FDA Approval of Medical Devices
People often think that a medical device is safe because it is approved by the FDA. Unfortunately, this is not the case. There are two ways for device manufacturers to obtain approval to market their products: Premarket Approval and 510(k) Premarket Notification. The first and most stringent is through the Premarket Approval process (“PMA”). PMA […]
Recent Developments in the Taxotere MDL
For the past five years, Stag Liuzza has litigated cases on behalf of women who suffered permanent alopecia, or hair loss, as a result of receiving a breast cancer chemotherapy drug called Taxotere. Plaintiffs claim that the manufacturers of the drug, including Sanofi-Aventis U.S., L.L.C. (“Sanofi”) and approximately twelve other pharmaceutical companies, failed to warn […]
Walmart Accused in U.S. Lawsuit of Fueling Opioid Crisis
The U.S. government accused Walmart Inc. of fueling a nationwide opioid crisis by ignoring warnings from its own pharmacists that the chain wasn’t properly set up to screen painkiller prescriptions in violation of federal regulations. The complaint filed Tuesday in Delaware comes two months after the world’s largest retailer filed its own case in Texas […]
Sacklers Face Furious Questions in Rare Testimony on Opioid Epidemic
Members of Congress on Thursday hurled withering comments and furious questions at two members of the billionaire Sackler family that owns Purdue Pharma, the maker of OxyContin, seeking to use a rare public appearance to extract admissions of personal responsibility for the deadly opioid epidemic as well as details about $10 billion that records show […]
The Sacklers’ Last Poison Pill
The opioid crisis remains one of America’s deadliest public health disasters. Victims demand answers about how it happened and who was responsible. The House Committee on Oversight and Reform seemed poised to address a facet of the crisis with a hearing this coming Tuesday on the role of Purdue Pharma and its owners, the Sackler […]
Bankruptcy judge OKs federal settlement with Purdue Pharma
[By GEOFF MULVIHILL] Proposed settlements between the federal government and OxyContin maker Purdue Pharma and its owners cleared a major legal hurdle Tuesday when a bankruptcy judge said they could move ahead. Last month, the company agreed to an $8.3 billion civil settlement with the U.S. Department of Justice related to claims about its role […]
Purdue’s massive opioid settlement is tangled in a bankruptcy court fight
By: BLOOMBERG Purdue Pharma’s massive settlement over claims that it helped spark the opioid crisis is facing pushback in federal court, creating a potential stumbling block for the landmark deal. Purdue has agreed to plead guilty to three felonies and pay $8.3 billion to settle federal investigations of how it marketed the painkiller OxyContin. But […]